IWR-1-endo CAS: 1127442-82-3
MF: C25H19N3O3
MW: 409.44
A potent inhibitor of the Wnt/β-catenin response.

IWR-1-endo (CAS 1127442-82-3)

IWR-1-endo | CAS 1127442-82-3 is rated 5.0 out of 5 by 1.
  • y_2020, m_2, d_17, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_295215, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 135ms
Synonym: 4-[(3aR,4S,7R,7aS)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl]-N-8-quinolinyl-benzamide
Application: A potent inhibitor of the Wnt/β-catenin response
CAS Number: 1127442-82-3
Purity: ≥98%
Molecular Weight: 409.44
Molecular Formula: C25H19N3O3
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

IWR-1-endo is a Wnt signaling protein, which are small secreted proteins that are active in embryonic development, tissue homeostasis, and tumorigenesis. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription. IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. It inhibits, at 10 μM, Wnt-induced accumulation of β-catenin, leading to proteasomal degradation of this protein through a destruction complex which consists of Apc, Axin2, Ck1, and Gsk3β. IWR-1-endo stabilizes the destruction complex, increasing the level of Axin2 protein without changing the levels of Apc or Gsk3β. The IWR compound does not change the de novo synthesis of Axin2, alter the affinity of Axin2 for β-catenin, or inhibit the proteasome. It has a half-life of 60 minutes in murine whole blood and 20 minutes in intact murine hepatocytes. In in vivo tests, IWR-1-endo inhibits zebrafish tail fin regeneration with a minimum inhibitory concentration of 0.5 μM. The IWR-1-exo diastereomer exhibits much less activity against the Wnt/β-catenin pathway and has been used as a control. IWR-1-endo is an inhibitor of Tankyrase-1 and Tankyrase-2.


1. Polakis, P., et al., 2000. Wnt signaling and cancer. Genes & development. 14(15): 1837-51. PMID: 10921899
2. Reya, Tannishtha., et al., 2005. Wnt signalling in stem cells and cancer. Nature. 434(7035): 843-50. PMID: 15829953
3. Clevers, Hans., et al., 2006. Wnt/beta-catenin signaling in development and disease. Cell. 127(3): 469-80. PMID: 17081971
4. Chen, Baozhi., et al., 2009. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature chemical biology. 5(2): 100-7. PMID: 19125156
5. Lu, Jianming., et al., 2009. Structure-activity relationship studies of small-molecule inhibitors of Wnt response. Bioorganic & medicinal chemistry letters. 19(14): 3825-7. PMID: 19410457

Appearance :
Physical State :
Solubility :
DMSO (~20 mg/mL), DMF (~20 mg/mL), and aqueous buffers (sparingly soluble).
Storage :
Store at -20° C
Melting Point :
310.51° C (Predicted)
Boiling Point :
~643.9° C at 760 mmHg (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D ~1.74 (Predicted)
IC50 :
Blocking a cell-based Wnt/β-catenin pathway reporter response: IC50 = 180 nM; Beta-catenin-dependent canonical Wnt3 pathway: IC50 = 26 nM (human); Proto-oncogene protein Wnt-3: EC5050 = 5 µM (human)
pK Values :
pKa: 11.88 (Predicted), pKb: 2.39 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
PubChem CID :
MDL Number :
C1C2C=CC1[[email protected]@H]3[[email protected]]2C(=O)N(C3=O)C4=CC=C(C=C4)C(=O)NC5=CC=CC6=C5N=CC=C6

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

IWR-1-endo  Product Citations

See how others have used IWR-1-endo. Click on the entry to view the PubMed entry .

Citations 1 to 8 of 8 total

PMID: # 30899376  Li, SJ.|Kao, YH.|Chung, CC.|Cheng, WL.|Chen, YJ.| et al. 2019. Am J Transl Res. 11: 744-754.

PMID: # 29055830  Fujita, S. et al. 2018. Bone. 106: 156-166.

PMID: # 27477297  Lu, C. et al. 2016. Toxicology. 365: 35-47.

PMID: # 26899563  Zhu, J. et al. 2016. Scientific reports. 6: 21549.

PMID: # 26048374  Mathur, R. et al. 2015. J Hematol Oncol. 8: 63.

PMID: # 26003048  Lee, S. et al. 2015. Molecular oncology. 9: 1599-611.

PMID: # 25963533  Xu, Z. et al. 2015. Journal of molecular neuroscience : MN. 56: 397-408.

PMID: # 21968810  Yasuhara, R. et al. 2011. Laboratory investigation; a journal of technical methods and pathology. 91: 1739-52.

Citations 1 to 8 of 8 total

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. IWR-1-endo, sc-295215, is in yellow powder form.
Answered by: Chemical Support 4
Date published: 2017-05-03
  • y_2020, m_2, d_17, h_19CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_295215, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 119ms
Rated 5 out of 5 by from Wang Wang, R. et al. (PubMed 26214410) investigated the role of musculoaponeurotic fibrosarcoma oncogene homolog K (MAFK) in osteosarcoma cell proliferation in vitro and the possible pathways that contributed to MAFK-related osteosarcoma development. A significant correlation between MAFK and the Wnt signaling pathway was observed with Wnt1-induced MAFK expression causing a significant increase in cell viability, while Wnt pathway inhibitor, IWR-1-endo, abolished Wnt1-induced effects on MAFK. -SCBT Publication Review
Date published: 2015-02-03
  • y_2020, m_2, d_17, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_295215, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 23ms

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.